Possible mechanism of adverse reaction following levodopa plus benserazide treatment.
1 Rats treated for seven days with seryl-trihydroxybenzylhydrazine (benserazide), and inhibitor of peripheral aromatic L-amino acid decarboxylase (500 mg/kg, daily, i.p.) alone or in combination with L-DOPA methylester (500 mg/kg, daily, i.p.) for seven days showed a moderate but significant decrease of liver aldehyde dehydrogenase (ALDH), without accompanying change in alcohol dehydrogenase (ADH) activity, compared with saline-treated controls. 2 Administration of L-DOPA methylester (500 mg/kg, daily, i.p.) alone for seven days had little effect on liver ADH or ALDH. 3. The combined treatment might be conducive to the in vivo formation of L-DOPA-derived tetrahydroisoquinoline derivatives which might be implicated in L-DOPA produced adverse effects.
D000429:Alcohol Oxidoreductases / Q000378:metabolism; D000445:Aldehyde Oxidoreductases / Q000378:metabolism; D000818:Animals; D001545:Benserazide / Q000009:adverse effects* / Q000494:pharmacology; D004347:Drug Interactions; D006834:Hydrazines / Q000009:adverse effects*; D007980:Levodopa / Q000009:adverse effects* / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051381:Rats; D013997:Time Factors
D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide; D000429:Alcohol Oxidoreductases; D000445:Aldehyde Oxidoreductases